Mayzent120 (Siponimod Tablet) 0.25mg

MAYZENT120 (Siponimod 0.25mg) is a prescription tablet used to treat relapsing forms of multiple sclerosis. This medication helps reduce flare-ups and slow disease progression. Store at 2-8°C and protect from light. Always follow healthcare provider guidance.

Strength

0.25mg

Pack Size

120s

Storage

2-8°

Manufacturer / TM Owner

Novartis pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Siponimod 0.25mg tablets are prescribed for adults with relapsing multiple sclerosis to decrease the frequency of clinical relapses and delay physical disability progression. It belongs to a class of drugs that modulate sphingosine-1-phosphate receptors, supporting immune system regulation. Patients often ask, 'what is Siponimod 0.25mg used for?' and this medication addresses that need within MS treatment plans.

Side Effects

After starting Siponimod 0.25mg, some patients notice reduced fatigue and fewer MS symptoms over time. Common effects may include mild dizziness or headache during the initial adjustment period. These effects vary by individual and should be discussed with a healthcare professional if persistent.

Precautions & Warnings

MAYZENT120 requires careful handling due to its temperature sensitivity; store refrigerated between 2-8°C and avoid freezing. Keep the blister pack sealed until use to protect from moisture. Patients with certain heart conditions should use this medication under close medical supervision.

Avoid Interactions

Siponimod may interact with other drugs that affect heart rhythm or CYP2C9 enzyme activity. Avoid combining with strong CYP2C9 inhibitors or drugs known to prolong QT interval. Alcohol and grapefruit products may also influence how this medication works, so discuss all current medications with your doctor.

Frequently Asked Questions

Siponimod 0.25mg is used to treat relapsing forms of multiple sclerosis in adults.

Store MAYZENT120 at 2-8°C in the original blister pack to protect from light and moisture.

Consult your healthcare provider before combining Siponimod with other drugs, especially those affecting heart rhythm or CYP2C9.

Some users report mild dizziness or headache when first starting Siponimod.

The safety of Siponimod during pregnancy has not been established; discuss risks with your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.